Results 181 to 190 of about 29,043 (297)

Task‐Aligned Haze Removal With Semantic‐Aware Fusion and Contrast Self‐Correction

CAAI Transactions on Intelligence Technology, EarlyView.
ABSTRACT Adverse haze conditions introduce complex degradations that obscure scene details and distort structural cues critical for object detection, posing persistent challenges for vision‐based sensing systems. Although existing haze removal methods have achieved notable improvements in visual clarity, their optimisation objectives are often ...
Jinbin Wang, Aiping Yang, Guosong Jiang, Wenlong Yu, Dongwei Ren, Qinghua Hu   +5 more
wiley   +1 more source

Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal. [PDF]

Eur J Neurol
Lopez Manzano C, Rice CM, Tallantyre E, Cooper C, Cooper C, Wang H, Tomlinson E, Sadek A, Rao-Middleton A, Thom H, Whiting P.   +10 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Predicting disease progression in multiple sclerosis with clinically accessible information and technology. [PDF]

J Neurol
Fuchs TAN, Schoonheim MM, Strijbis EMM, Jelgerhuis JR, Horakova D, Havrdova EK, Uher T, Zivadinov R, Ozakbas S, Girard M, Alroughani R, Grammond P, Lugaresi A, Tomassini V, Kalincik T, Roos I, Gerlach O, van der Walt A, Khoury SJ, van Pesch V, Surcinelli A, Foschi M, Sa MJ, D'amico E, Kuhle J, Cartechini E, Maimone D, Karabudak R, Soysal A, Spitaleri D, Laureys G, Taylor B, D'hooghe M, Ampapa R, Castillo-Triviño T, Altintas A, Gray O, Gouider R, Meca-Lallana JE, Kermode AG, Fabis-Pedrini M, Carroll WM, de Gans K, Sanchez-Menoyo JL, Etemadifar M, Al-Asmi A, McCombe P, Simu M, Yetkin MF, Al-Harbi T, Csepany T, Lalive P, Hardy TA, Ramanathan S, Willekens B, Sempere AP, Cárdenas-Robledo S, Habek M, Singhal B, Grigoriadis N, Simo M, Shaygannejad V, Blanco Y, Aguera-Morales E, Garber J, Solaro C, Shuey N, Khurana D, Decoo D, Moghadasi AN, Buzzard K, Skibina O, John N, Petersen T, Weinstock-Guttman B.   +74 more
europepmc   +1 more source

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

Addiction, EarlyView.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen, Irma S. van den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink   +5 more
wiley   +1 more source

Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis. [PDF]

J Neurol
Guo J, Olsson T, Johansson E, Alfredsson L, Hedström AK.   +4 more
europepmc   +1 more source

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, EarlyView.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort Study. [PDF]

Eur J Neurol
Savolainen M, Soilu-Hänninen M, Nurmi H, Viitala M, Tienari P, Atula S, Laakso SM.   +6 more
europepmc   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants. [PDF]

Transl Psychiatry
Erne L, Mueller L, Straumann I, Ademaj B, Eckert A, Vukalovic I, Valenta J, Luethi D, Liechti ME, Vogt SB.   +9 more
europepmc   +1 more source